Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 recombinant von Willebrand factor study for bleeding episodes in severe von Willebrand disease
NL-OMON38008Phase 3Recruiting
- Sponsor
- Baxter International Inc.
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vonicog alfa and recombinant human coagulation factor VIII in von Willebrand disease (VWD) (4 arms), sponsored by Baxter International Inc. Primary endpoint: Treatment success for treated bleeding episodes. Started Jul 2012; status: recruiting.
02
Drugs
vonicog alfarecombinant human coagulation factor VIII
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NL-OMON38008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38008.